tqb2450
mAbexperimental
Clinical trial activity
74 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
65
Phase 3
13
Phase 4
1
Earliest trial started Mar 15, 2018 (NCT03460457)
Timeline
Indications
Studied for
- Ablation Techniques · Phase 3
- Angiogenesis Modulating Agents · Phase 3
- Biliary Tract Neoplasms · Phase 3
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Small Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Chemoradiotherapy · Phase 1
- Cholangiocarcinoma · Phase 1/Phase 2
- Digestive System Diseases · Phase 2
- Digestive System Neoplasms · Phase 2
- Drugs, Investigational · Phase 3
- Endometrial Neoplasms · Phase 3
- Esophageal Diseases · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Gastrointestinal Diseases · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Genital Neoplasms, Female · Phase 1/Phase 2
- Hepatitis B, Chronic · Phase 2
- Immunotherapy · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 2
- Melanoma · Phase 1/Phase 2
- Molecular Targeted Therapy · Phase 2
- Mouth Neoplasms · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoadjuvant Therapy · Phase 2
- Neoplasms · Phase 3
- Neoplasms by Histologic Type · Phase 2
- Neoplasms by Site · Phase 2
- Neoplasms, Squamous Cell · Phase 2
- Ovarian Neoplasms · Phase 3
- Pancreatic Neoplasms · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Programmed cell death 1 ligand 1ANTAGONIST
PDL1
- Programmed cell death 1 ligand 1Immunity, passive
CD274 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315042 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07294261 | Phase 2 | Dec 23, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Sun Yat-Sen University |
| NCT07172412 | Phase 2 | Nov 30, 2025 | Tianjin Medical University |
| NCT07193186 | Phase 2 | Oct 1, 2025 | Fudan University |
| NCT07109167 | Phase 2 | Aug 1, 2025 | Shandong first medical University |
| NCT06953843 | Phase 2 | Jul 9, 2025 | People's Liberation Army of China |
| NCT06848439 | Phase 2 | Jun 15, 2025 | Jiangsu Cancer Institute & Hospital |
| NCT06978153 | Phase 2 | May 20, 2025 | People's Liberation Army of China |
| NCT06874933 | Phase 2 | May 4, 2025 | Zhejiang University |
| NCT06914297 | Phase 2 | Apr 21, 2025 | Fudan University |
| NCT06931145 | Phase 4 | Apr 15, 2025 | Chinese Academy of Medical Sciences, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06992336 | Phase 2 | Apr 10, 2025 | Sun Yat-Sen University |
| NCT06897579 | Phase 2 | Apr 7, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06851169 | Phase 2 | Apr 1, 2025 | People's Liberation Army of China |
| NCT06733051 | Phase 2 | Dec 31, 2024 | Sun Yat-Sen University |
| NCT06699498 | Phase 2 | Dec 3, 2024 | Nanjing Medical University |
| NCT06767800 | Phase 2 | Nov 21, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06637163 | Phase 2 | Oct 31, 2024 | Fudan University |
| NCT06662006 | Phase 2 | Oct 31, 2024 | Nanjing University |
| NCT06621095 | Phase 2 | Oct 30, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Jiao Tong University |
| NCT06603974 | N/A | Oct 16, 2024 | Xijing Hospital |
Showing 20 of 74 trials
Page 1 / 4
Organizations
Research & Development (21)
21 organizations
Page 1 / 2